Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis - KMPH FOX 26 | Central San Joaquin Valley News Source

Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Decision Resources Group

Interest in GCS-100, Velcalcetide, ST-10, GSK-1278863A and Rayaldee Ranges from Moderate to High, According to Findings from Decision Resources Group

BURLINGTON, Mass., July 10, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of surveyed nephrologists report awareness of the U.S. Food and Drug Administration's (FDA) approval of Vifor Fresenius Medical Care Renal Pharma's new phosphate binder Velphoro, which was approved by the FDA in November 2013 for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.

Decision Resources Group Logo.

Other key findings from the report entitled TreatmentTrends: Nephrology (US) Q2 2014:

  • Bundling: Based on mean ratings, surveyed nephrologists are under the most pressure from their dialysis unit to restrict measurement of nonessential labs, to use lower doses of erythropoiesis-stimulating agents (ESAs) and to have more stringent hemoglobin targets resulting in less ESA use. Surveyed nephrologists believe that the delay of inclusion of oral dialysis drugs into the end-stage renal disease payment bundle will similarly impact future use of phosphate binders, oral iron and Amgen's Sensipar.
  • IV Iron patient share in hemodialysis (HD): American Regent/Fresenius Medical Care's Venofer has significantly declined in reported HD patient share compared with this time period last year.
  • Nephrologists' perceptions of late-stage compounds in clinical development: The report discusses aided familiarity, interest and percentage of patients as likely candidates for 12 renal products in development after review of product profiles. New product profiles added to this quarter's report, include:
    • LaJolla Pharmaceutical's GCS-100: Nearly half of nephrologists report high interest in the product, which was higher than all other renal anemia and bone mineral metabolism products in late-stage development covered in this study.
    • GSK's GSK-1278863A: Nearly one-third of nephrologists report high interest in this oral renal anemia product.
    • Shield Therapeutics' ST-10: Nearly a third of nephrologists report high interest in this oral ferric iron therapy.
    • Amgen's Velcalcetide: Should this intravenous therapy for secondary hyperparathyroidism (SHPT) receive FDA approval, nephrologists expect significantly higher usage in the dialysis versus the CKD non-dialysis (ND) setting.
    • OPKO Health's Rayaldee: While familiarity is low, over 40 percent of nephrologists report high interest in this oral Vitamin D therapy used to treat SHPT being tested in CKD stage 3 and stage 4 patients, after review of a product profile.

Comments from Decision Resources Group Director Rob Dubman:

  • "Physicians are recalling lower number of pills as one of Velphoro's primary messages from sales representatives. Not surprisingly, we have found that in this and other studies that delivery attributes are not as important compared with efficacy and safety attributes." 

Additional Resources:

A special report that is expected to publish later this month entitled The Impact of New Iron-Based Phosphate Binders on the Hyperphosphatemia Market will also help manufacturers understand why and how Velphoro and Keryx Pharmaceutical's Zerenex will be used, if Zerenex receives FDA approval later this year.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

©2012 PR Newswire. All Rights Reserved.

  • Local NewsLocal NewsMore>>

  • How To Spot A Fake Debt Collector

    How To Spot A Fake Debt Collector

    If a debt collector comes calling, you should go researching. That's the new advice coming from Yahoo! Finance to avoid getting scammed.Even if you get swindled, you're still on the hook to a real debt collector! That's the law.One way to spot a fraud is to look at how old the debt is. If it's 10 to 15 years old, chances are there aren't grounds for a lawsuit.Mandi Woodruff of Yahoo! Finance recommends, “Another way you can tell if you're dealing with a fraud or not is to look at the name of ...More >>
    If a debt collector comes calling, you should go researching. That's the new advice coming from Yahoo! Finance to avoid getting scammed.Even if you get swindled, you're still on the hook to a real debt collector! That's the law.One way to spot a fraud is to look at how old the debt is. If it's 10 to 15 years old, chances are there aren't grounds for a lawsuit.Mandi Woodruff of Yahoo! Finance recommends, “Another way you can tell if you're dealing with a fraud or not is to look at the name of ...More >>
  • Peanut Allergies No More!

    Peanut Allergies No More!

    Good news for the three million Americans who are allergic to peanuts.Researchers at North Carolina A T's School of Agriculture developed a new technique to remove peanut allergens.They say shelled and skinless peanuts can be treated with an enzyme that breaks down certain proteins that can trigger food–related allergies.Researchers say the process does not change the peanut's shape or shelf life.For more info, click HERE for the USDA info.More >>
    Good news for the three million Americans who are allergic to peanuts.Researchers at North Carolina A T's School of Agriculture developed a new technique to remove peanut allergens.They say shelled and skinless peanuts can be treated with an enzyme that breaks down certain proteins that can trigger food–related allergies.Researchers say the process does not change the peanut's shape or shelf life.For more info, click HERE for the USDA info.More >>
  • Church in Northwest Fresno Vandalized

    Church in Northwest Fresno Vandalized

    Police are looking for the vandal that left the walls and front door of a northwest Fresno church spray painted. An administrator at St. Anthony of Padua church discovered the graffiti Saturday morning when arriving to work.One of the churches front doors and the walls around it had been spray painted with bizarre images and words.If you have any information that could help police identify the person who did this, call the Fresno Police Department at 559-621-7000.More >>
    Police are looking for the vandal that left the walls and front door of a northwest Fresno church spray painted. An administrator at St. Anthony of Padua church discovered the graffiti Saturday morning when arriving to work.One of the churches front doors and the walls around it had been spray painted with bizarre images and words.If you have any information that could help police identify the person who did this, call the Fresno Police Department at 559-621-7000.More >>
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KMPH. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.